Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with A
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q3 2022 | ANHYDROUS LACTOSE | ORAL | TABLET, DELAYED RELEASE | 3250mg | Correction | ||
| Q4 2022 | ANHYDROUS LACTOSE | ORAL | TABLET, DELAYED RELEASE | 1083mg | Correction | ||
| Q4 2022 | ADIPIC ACID | VAGINAL | TABLET | 57.00 mg | Deletion | ||
| Q4 2022 | ANHYDROUS CITRIC ACID | ORAL | LIQUID, EXTENDED RELEASE | 5.18 mg/ 1.00 ml | 62mg | Deletion | |
| Q4 2022 | ANHYDROUS TRISODIUM CITRATE | ORAL | LIQUID, EXTENDED RELEASE | 3.90 mg/ 1.00 ml | 47mg | Deletion | |
| Q3 2022 | ADIPIC ACID | VAGINAL | INSERT | 57.00 mg | MDE Replacement | ||
| Q4 2022 | ADIPIC ACID | VAGINAL | INSERT | 171mg | MDE Replacement | ||
| Q3 2022 | AMMONIUM ACETATE | INTRAMUSCULAR | INJECTION | 0.80 %w/v | MDE Replacement | ||
| Q4 2022 | AMMONIUM ACETATE | INTRAMUSCULAR | INJECTION | 160mg | MDE Replacement | ||
| Q3 2022 | AMMONIUM ACETATE | INTRAVENOUS | INJECTION | 0.80 %w/v | MDE Replacement | ||
| Q4 2022 | AMMONIUM ACETATE | INTRAVENOUS | INJECTION | 160mg | MDE Replacement | ||
| Q3 2022 | AMMONIUM SULFATE | INTRAVENOUS | INJECTABLE, LIPOSOMAL | 0.20 %w/v | MDE Replacement | ||
| Q4 2022 | AMMONIUM SULFATE | INTRAVENOUS | INJECTABLE, LIPOSOMAL | 81mg | MDE Replacement | ||
| Q3 2022 | ANHYDROUS CITRIC ACID | INTRAVENOUS | INJECTION, SOLUTION | 0.53 %w/v | MDE Replacement | ||
| Q4 2022 | ANHYDROUS CITRIC ACID | INTRAVENOUS | INJECTION, SOLUTION | 540mg | MDE Replacement | ||
| Q3 2022 | ANHYDROUS CITRIC ACID | ORAL | SUSPENSION | 720.00 mg | MDE Replacement | ||
| Q4 2022 | ANHYDROUS CITRIC ACID | ORAL | SUSPENSION | 300mg | MDE Replacement | ||
| Q3 2022 | ANHYDROUS CITRIC ACID | ORAL | SUSPENSION/ DROPS | 2.50 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2022 | ANHYDROUS CITRIC ACID | ORAL | SUSPENSION/ DROPS | 14mg | MDE Replacement | ||
| Q3 2022 | ASCORBIC ACID | TOPICAL | GEL | 0.30 %w/w | MDE Replacement | ||
| Q4 2022 | ASCORBIC ACID | TOPICAL | GEL | 3mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: October 1, 2022
Database Last Updated: October 19, 2022